Oncoemataig lives shift paradigm With new cures that show a promising product in the treatment of both types leukemia Most common in adults: chronic lymphocytic leukemia (CLL) and myeloid acute leukemia (AML), which accounts for 60% of all the flavors that have been detected in Argentina. These developments were today exhibited at the American Hematology Association (ASH) Transportation, which was held in San Diego, United States, where they could see the patient-receiving outcomes Fairly permanent permanent grades for some patient groups.
Regarding the LLC in Congress, the advances at the 3-stage Murano study, Confirms a combination of venetoclax and rituximab drugs for patients given by this type of leukemia. A global of 389 patients from 20 countries will participate in their work. Out of the 130 patients who completed a complete cure course and then stopped it, The approximate approximation of a & # 39; War 6 and 12 months 92 and 87%, respectively. The three years of livelihood – what are the new results found in this phase of the study? 87.9%, according to the full-time exhibition by the research author, John Seymour, Director of Oncology Medicine at Peter MacCallum's Center in Australia.
"This is a good news for patients and the medical community, because there have been no new drugs for a long time and that the results were not limited and with poor incidents. Changes from an intravenous medicine drug to oral remedy, what has changed the front of the illness, as it is also provided for a limited time and then it is broken, "it is the definition. Clarin Alicia Enrico, doctor at the Italian Hospital of La Plata and co-ordinator of the research field.
This new medicine includes two years of oral treatment, along with a & # 39; Other drugs involved in a smaller period. "Once it is hanged, patients will continue to be pardoned without taking medication and their & Living. This is completely innovative. They have been cared for 36 months and 87% of patients have very good results, "and add Enrico to him.
In Argentina, the two drugs (venetoclax and rituximab) have been agreed as a medicine. Now, ANMAT is in the final stages of assessment for approval in the coming months to be used together.
CLL is a type of cancer that affects blood and bone marrow. It is marked by an accelerated generation of unusual white blood cells. These cells, when they perform the action, are over fighting diseases. It represents 30% of the hidden objects in adults. It usually occurs in patients over 70 years and is twice as common in men than in women. Out of the total LLC, it is estimated that current treatment of 30% of the product is required; Patient must be confirmed, another 30% must have a their life at any time, but in the first place the patient will be followed until there is a disease and then needs to be treated. And the proportion will not be needed; may have been cure ever
In the case of a mentally-behavioral, it is another type of blood cancer; It's one of the biggest cancer because it's a? grow rapidly and without control. Most of them will have a & # 39; affecting primitive or unnecessary cells, which compile in a & # 39; bone marrow and remote blood. These cells can not fulfill their actions improving its disease is accelerated. In general, patients diagnosed by this leukemia are those who are get worse and about 40% of them – are not allowed for chemotherapy due to decisive decisions or age – they had poor handling options, so the 6-month duration would last. It usually happens in people over 45 years of age and a 68 year old age of judgment.
At ASH transport, two studies were provided containing venetoclax with two types of drugs, and those used in the case; This patient group is unsuitable for severe chemotherapy: two non-health and cytarabine lighters. The first of these two reviews – which was & # 39; Using venetoclax with hypomethylating representatives – led by researcher Daniel Pollyea from the University of Colorado, Denver, USA. The second, with Andrew Wei, from Alfred's Hospital and Monash University in Melbourne, Australia, was together with the low dose of Cytarabine. In both studies, they met high levels of reference (about 60%) and medium live of 17 months, which represents important progress for patients with no effective cure. These combinations have been accepted a few weeks ago with the FDA, so it is likely that this new medicine may come to Argentina in a period of about one year.
"Patients who benefit from this new treatment are those who can not, according to age or sympathy, get severe chemotherapy, because the same chemo can cause death." For those with very poor choices, those drugs, hypomethylating and cytarabine agents in low doses, but lasting six months, "he says. Clarin Dr. Hernán Dick, oncoematics specializing in AML at the Italian Hospital of La Plata. "These surveys had amazing results, by linking each one with venetoclax, 70% of total and medium responses for 16 or 17 months," doctor of Gutiérrez de La Plata Hospital.
It is estimated that some of them are found in Argentina 2,300 new cases of fluphy in the year, according to data from the National Cancer Institute.
San Diego (United States). Special Will.